An inactivated vaccine based on artificial non-pathogenic fowl adenovirus 4 protects chickens against hepatitis-hydropericardium syndrome

文献类型： 外文期刊

第一作者： Zhang, Yu

作者： Zhang, Yu;Liu, Aijing;Cui, Hongyu;Qi, Xiaole;Liu, Changjun;Zhang, Yanping;Li, Kai;Gao, Li;Wang, Xiaomei;Pan, Qing;Gao, Yulong;Wang, Xiaomei

作者机构：

关键词： Fowl adenovirus 4; Hepatitis-hydropericardium syndrome; Inactivated vaccine; Recombinant virus; Biosafety

期刊名称：VETERINARY MICROBIOLOGY （ 影响因子：3.246； 五年影响因子：3.565 ）

ISSN： 0378-1135

年卷期： 2022 年 264 卷

页码：

收录情况： SCI

摘要： Hepatitis-hydropericardium syndrome (HHS) in birds is mainly caused by virulent fowl adenovirus 4 (FAdV-4). A novel genotype, hypervirulent FAdV-4, emerged in 2015 with a high mortality rate ranging from 30 % to 100 % in chickens. Vaccination is an economically feasible method to control HHS. Although there have been various reports of inactivated vaccines from virulent wild-type FAdV-4 against HHS, biosafety threats of inactivated vaccines from potential pathogenic components have been presented to the poultry industry, and safer vaccines are urgently needed. A non-pathogenic recombinant FAdV-4 strain, designated as rHN20, was generated based on the hypervirulent strain in our previous study. Here, we developed a novel inactivated oil-adjuvanted vaccine derived from rHN20 strain and evaluated its immunogenicity in specific-pathogen-free chickens. Chickens subcutaneously or intramuscularly immunized with the inactivated vaccine produced high titers of neutralizing antibodies and were protected from a lethal dose of virulent wild-type FAdV-4 challenge. Collectively, an inactivated vaccine was developed, which was capable of providing full protection for chickens against HHS, and significantly reduced the potential biosafety threats.

分类号：

  • 相关文献
作者其他论文 更多>>

微信小程序